New weight loss pill offers needle-free option as demand for GLP-1 drugs surges

A new option is now available for millions of Americans looking to lose weight — without the need for injections.

(NBC)- A new option is now available for millions of Americans looking to lose weight — without the need for injections.

Eli Lilly has received FDA approval for its new GLP-1 weight loss pill, Foundayo, which is expected to hit the market next week.

The pill enters a rapidly growing market, following the release of an oral version of Wegovy from Novo Nordisk earlier this year.

Unlike other options, Foundayo is designed for convenience. Patients can take it at any time of day, without worrying about food restrictions — a key difference from Wegovy’s pill, which must be taken on an empty stomach with a waiting period before eating or drinking.

“You can take it any time of day, without regard to food. It’s just simple,” said Eli Lilly CEO Dave Ricks.

Experts say that ease of use could significantly expand the already booming weight loss drug industry, which is projected to grow from $73 billion this year to $250 billion by 2034.

“I think people are generally very excited about an oral GLP-1,” said Dr. Shauna Levy. “The fact that this can be taken so easily is incredibly important.”

For some patients, the appeal is simple — avoiding needles.

“I never tried an injectable… mainly because I just don’t like needles,” said Maggie Linton, a 77-year-old who participated in clinical trials for the drug.

Linton says she lost 60 pounds over two years while taking Foundayo.

While studies show injectable versions remain more effective, the pill still delivers significant results. Patients taking the highest dose of Foundayo lost an average of 12 percent of their body weight — about 27 pounds.

Cost, however, could limit access. The new pill is priced similarly to Wegovy, with starter doses around $149 per month for cash-paying customers. Higher doses can cost up to $349 per month.